2m68: Difference between revisions
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==NMR solution structure ensemble of 3-4D mutant domain 11 IGF2R in complex with IGF2 (domain 11 structure only)== | ==NMR solution structure ensemble of 3-4D mutant domain 11 IGF2R in complex with IGF2 (domain 11 structure only)== | ||
<StructureSection load='2m68' size='340' side='right' caption='[[2m68 | <StructureSection load='2m68' size='340' side='right'caption='[[2m68]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2m68]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2M68 OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[2m68]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2M68 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2M68 FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 20 models</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2m68 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2m68 OCA], [https://pdbe.org/2m68 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2m68 RCSB], [https://www.ebi.ac.uk/pdbsum/2m68 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2m68 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/MPRI_HUMAN MPRI_HUMAN] Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4.<ref>PMID:10900005</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Among the 15 extracellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domain 11 has evolved a binding site for IGF2 to negatively regulate ligand bioavailability and mammalian growth. Despite the highly evolved structural loops of the IGF2:domain 11 binding site, affinity-enhancing AB loop mutations suggest that binding is modifiable. Here we examine the extent to which IGF2:domain 11 affinity, and its specificity over IGF1, can be enhanced, and we examine the structural basis of the mechanistic and functional consequences. Domain 11 binding loop mutants were selected by yeast surface display combined with high-resolution structure-based predictions, and validated by surface plasmon resonance. We discovered previously unidentified mutations in the ligand-interacting surface binding loops (AB, CD, FG, and HI). Five combined mutations increased rigidity of the AB loop, as confirmed by NMR. When added to three independently identified CD and FG loop mutations that reduced the koff value by twofold, these mutations resulted in an overall selective 100-fold improvement in affinity. The structural basis of the evolved affinity was improved shape complementarity established by interloop (AB-CD) and intraloop (FG-FG) side chain interactions. The high affinity of the combinatorial domain 11 Fc fusion proteins functioned as ligand-soluble antagonists or traps that depleted pathological IGF2 isoforms from serum and abrogated IGF2-dependent signaling in vivo. An evolved and reengineered high-specificity M6P/IGF2R domain 11 binding site for IGF2 may improve therapeutic targeting of the frequent IGF2 gain of function observed in human cancer. | |||
Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.,Frago S, Nicholls RD, Strickland M, Hughes J, Williams C, Garner L, Surakhy M, Maclean R, Rezgui D, Prince SN, Zaccheo OJ, Ebner D, Sanegre S, Yu S, Buffa FM, Crump MP, Hassan AB Proc Natl Acad Sci U S A. 2016 May 17;113(20):E2766-75. doi:, 10.1073/pnas.1513023113. Epub 2016 May 2. PMID:27140600<ref>PMID:27140600</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 2m68" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
*[[Insulin-like growth factor receptor|Insulin-like growth factor receptor]] | *[[Insulin-like growth factor receptor|Insulin-like growth factor receptor]] | ||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Crump | [[Category: Homo sapiens]] | ||
[[Category: Frago | [[Category: Large Structures]] | ||
[[Category: Garner | [[Category: Crump MP]] | ||
[[Category: Hassan | [[Category: Frago S]] | ||
[[Category: Hoppe | [[Category: Garner L]] | ||
[[Category: Hughes | [[Category: Hassan AB]] | ||
[[Category: Minnall | [[Category: Hoppe H]] | ||
[[Category: Prince | [[Category: Hughes J]] | ||
[[Category: Rezgui | [[Category: Minnall L]] | ||
[[Category: Richards | [[Category: Prince SN]] | ||
[[Category: Strickland | [[Category: Rezgui D]] | ||
[[Category: Whittaker | [[Category: Richards E]] | ||
[[Category: Williams | [[Category: Strickland M]] | ||
[[Category: Zaccheo | [[Category: Whittaker S]] | ||
[[Category: Williams C]] | |||
[[Category: Zaccheo OJ]] | |||